Endometriosis Imaging Study Highlights 99mTc-Maraciclatide as Diagnostic and Monitoring Tool

Key Takeaways

• 99mTc-maraciclatide detected endometriosis in 14 of 17 surgical positives
• No false positives reported in the Phase 2 DETECT study
• Imaging identified lesions missed by standard ultrasound or MRI
• Works for superficial peritoneal, ovarian, and thoracic endometriosis
• FDA granted Fast Track; Phase 3 trials now underway

Pulse Analysis

Endometriosis affects an estimated 10 % of reproductive‑age women, yet the average diagnostic interval exceeds seven years because definitive confirmation still requires laparoscopy. Conventional imaging—ultrasound and MRI—often fails to reveal superficial peritoneal lesions, which represent the majority of early‑stage disease. In this context, molecular imaging agents that target disease‑specific pathways are gaining attention. 99mTc‑maraciclatide binds to αvβ3 integrin, a protein up‑regulated during the angiogenesis that fuels endometrial implants, offering a biologically driven alternative to anatomy‑based scans.

The Phase 2 DETECT trial enrolled 19 women undergoing diagnostic laparoscopy and demonstrated a 74 % detection rate (14 of 17) for surgically confirmed lesions, with perfect specificity—no false‑positive scans. Importantly, the tracer visualised lesions that standard modalities missed, including two cases of thoracic endometriosis, and performed consistently across superficial peritoneal, ovarian and deep infiltrating subtypes. Patients reported high tolerability, and the gamma‑emitting signal enabled straightforward planar imaging, positioning 99mTc‑maraciclatide as a practical tool for both initial diagnosis and longitudinal monitoring of treatment response.

Regulatory momentum is already evident: the FDA granted Fast Track designation, accelerating the path to a pivotal Phase 3 study and eventual market entry. A non‑invasive, integrin‑targeted scan could reshape the endometriosis care pathway, reducing surgical referrals, streamlining therapeutic trials, and opening revenue streams for imaging companies. Moreover, the technology may be adaptable to other angiogenesis‑driven conditions, extending its commercial appeal. As insurers and providers seek cost‑effective diagnostics, 99mTc‑maraciclatide stands poised to become a cornerstone of women’s‑health imaging.